

HealthTech Innovation Days

October 5&6 2020 at the Peninsula Paris and virtually



Focus on

Covid-19 : European economic impact on the healthcare ecosystem and strategy
Interventions of :



Emmanuel Macron

French President

Speaker during the Opening Ceremony

Link to the replay : <https://htid-paris.streameo.fr/E1.html>



Thierry Breton

Commissioner at European Commission, Internal Market

Speaker during the Opening Ceremony

Link to the replay : <https://htid-paris.streameo.fr/E1.html>



Nicolas Dufourcq

CEO at Bpifrance

Speaker during the Opening Ceremony

Link to replay : <https://htid-paris.streameo.fr/E1.html>

Interviews of :



Christian Pierret

Former French Minister of Industry

Speaker at «Economic impact of Covid-19 on the healthtech ecosystem»



Stewart Cole

President of the Pasteur Institut in Paris

Speaker at «Economic impact of Covid-19 on the healthtech ecosystem»

Covid-19 : European economic impact on the healthcare ecosystem and strategy



Emmanuel Macron
French President

"I am very pleased to introduce these HealthTech Innovation Days and, I want to start by thanking you all for setting up and maintaining this event ... it confirms the interest you all have in the French healthtech ecosystem.

A lot has changed in the past three years, with modernized France, improved funding, simplified processes ... but big changes are in front of us.

The COVID-19 crisis revealed our strong dependence on other countries for many medical products ... efforts on re-location are necessary but I believe they are insufficient for our ecosystem. France remains a medium size ecosystem and we know we can do much better ... the key to a powerful health system is innovation ... Today my ambition is how do we make France a world leader in health technology by 2030! The first European country for the production of new medicines! How do we make France the next Boston in a nutshell!

To do this we are working on, first research, ... second financing innovation on bioproduction and digital health ... third simplicity and visibility, starting in 2021 we will significantly simplify the temporary utilization process for medicines and medical devices ... fourth access to talent ... and fifth none of this can be done by France alone we need the European market to open up! We need to invent new mechanisms such as the European BARDA ... this is crucial to keep transforming Europe.

The time will come for recovery, France needs to become the place where companies and products are invented, produced and brought to international markets.

This is our strategy, our willingness and for that I am counting on you"

"In the recent months, the coronavirus pandemic has taken a huge toll on human life causing a dramatic impact on our economy and putting health and social systems across Europe under unprecedented pressure. The economic impact on our industry has been mixed ... some companies had to increase their production to respond to the surge in demand of top priority products ... in other cases demand dropped ... however, we have also witnessed an acceleration of the development of new medical technologies based on cutting edge discovery.

The pandemic has prompted a renewed urgency in unlocking the potential of digital tools in the health sector and in accelerating the digital transformation of health care. Digital has a key role to play here ..."



Thierry Breton
Commissioner at European
Commission, Internal Market



Nicolas Dufourcq
CEO of Bpifrance

"The past six months were quite a challenge, with the PGE, whose guarantee is managed by Bpifrance, the state, the banks and Bpifrance have contributed to supplying the French economy with 120 G€ of liquidity. On top of that we had some sectorial priorities, the industry the health sector was identified, pinpointed notably in the massive subsidy program ... for a multi-billion program.

On Monday October 12, with the Minister of Health I will launch the digital health plan for France in which Bpifrance is involved. Last year we financed 450 projects in the biotech field for total of 150 million euros ... and at the same time, we invested 85 million euros in equity in biotech start-ups ... and it will not change in 2020 ... we do not want to stop!

On top of that, we decided this year an allocation of resources dedicated to research on COVID-19. ... 80 million euros on collaboration projects for clinical development of drugs and vaccines ... and 120 million euros to finance projects to increase industrial capacities.

We continue also to push the Deep Tech plan launched in 2019 which is a partnership with the French universities and research laboratories ... to trigger the creation by researchers of start-ups because if there is a weakness in France today it is not so much in financing ... what we still don't have enough is the real desire by researchers to create their start-up. It's working well ... there is a culture change in universities, something is happening ...

In France there is a total commitment from the top to the laboratory with a sense of continuity which is essential for success and there is a bank, BPI, which is completely committed to achieve the vision."

"For the second year, HealthTech Innovation Days have brought together in Paris leading private and public European and International stakeholders. Bristol Myers Squibb is pleased to support this key annual event, as well as the development of a vibrant healthtech ecosystem, by partnering with academic centers and innovative companies, with the ultimate goal to transform the life of patients through science." **Bristol Myers Squibb**

Covid-19 : European economic impact on the healthcare ecosystem and strategy



Christian Pierret,
Former French Minister of Industry
«All over the world sufficient money to finance what we are»



Stewart Cole, President of the **Pasteur Institut in Paris**
« We need to invest more in R&D for emerging infectious diseases »

Well, this event takes place in a very important moment of the economic world life. That's to say at the moment where the COVID-19 raises deep and difficult questions about the future of the economy, the conditions of growth, and what is to do to remain optimistic and to remain proactive in this world economy.

We, who know the kind of upheaval and the risks in terms of job destruction, of growth, of development and of equality between the different countries of the world, have chosen to give a demonstration that it is possible to be confident in the future. And this confidence is based on **two main issues**.

The first is that here everything that is said and done is aimed at the **development of investment and R&D**. And we know that new growth for decades to come will be based on innovation and more investment than in the past.

The first problem is therefore to say very clearly that investment is essential, that R&D is essential, that science is essential.

The second remark is that, **nothing is possible without entrepreneurship, without this kind of confidence** that is the resilience of the leaders of the economy and of companies. And nothing is possible without any support from **local authorities**. I mean the states, but I mean essentially the European Union, for instance.

Regarding Europe, and international organizations, we are sure that nothing is possible if all, at the global level, we do not decide to cooperate to make efforts at the different levels such as companies, countries, states, organizations, to converge and to collaborate efficiently with each other.

So, entrepreneurship, support of public bodies and confidence, investment and research **are all key**. And here this sector represents probably one of the four or five domains, which are on the edge to win in this worldwide battle. There is **all over the world sufficient money to finance what we are**, what is at stake here and to mobilize this money, you should go through a demonstration that, confidence to go forward after the COVID-19.

And, as the philosopher said, what doesn't kill me, doesn't weaken me but reinforce my own ability to win.

During the roundtable dedicated to the "Economic impact of Covid-19 on the Health Tech ecosystem", I explained a little bit the history of the Pasteur Institute, how it has been active in the field of infectious disease research, immunology and global health since its beginning, and how our founder, Louis Pasteur, **was a pioneer in the area of translational research, ensuring that all of his discoveries were turned into applications of benefit to humanity.**

The discussion was very interesting because it addressed the impact of covid-19 on the health tech sector and discussed both the threats and the opportunities which were arising.

There were many opportunities, and in order to make the most of these opportunities, I think there are a couple of take-home messages which I would like to impart.

The first of these is that we need a **more level playing field in terms of funding for translational research in Europe**. Our American colleagues for many years have had extensive support from BARDA, a government agency which puts public money into what I perceive as projects of major impact in the health sector. In Europe, we do not have an equivalent agency, and I think it's time that such an agency to be created so that we could compete on level terms.

The second message that I think the most important is **to do with emerging infectious diseases**. And during the past 20 years, we've had three major outbreaks of coronavirus infections, the latest one being SARS coronavirus, to be responsible for covid-19, which has caused incalculable suffering, loss of life and huge economic losses.

Of course, in order to prevent such major disruption to society, to our economies and to the world moving forward, **WE NEED TO INVEST MORE IN R&D FOR EMERGING INFECTIOUS DISEASES.**

"A pleasure for BNP Paribas to attend the second edition of the HealthTech Innovation Days conference, which successfully offered an alternative format in the current Covid environment to meet a multitude of exciting biotech companies. We look forward to attending the third edition and deepening and enhancing our relationship with the participants"

**Dr. Zahid Moneer, PhD, MBA (Cantab) Managing Director Investment Banking, Healthcare
BNP Paribas – CIB – Global Banking**



PROGRAM 2020

<https://htid-paris.streameo.fr>



October 5th – Salon Etoile

12:50 – 2:00 PM : Grand Opening & Venture Centre of Excellence Programme Launch

Speakers:

Jan-Philipp Beck, CEO EIT Health
Jean-Marc Bourez, Managing Director of EIT Health France and Head of the VCoE
Thierry Breton, Commissioner at European Commission, Internal Market
Hubert Cottogni, Director and Head of Mandate Management
Alexandra Dublanche, Representative of Ile-De-France Region
Nicolas Dufourcq, CEO at Bpifrance
Maryvonne Hiance, President of HealthTech For Care
Franck Mouthon, President France Biotech and CEO of TheraNexus

2:00 – 3:00 PM : Keynote – Economic impact of Covid-19 on the healthtech ecosystem

Moderated by Christian Pierret, Former French Minister of Industry

Speakers :

Philippe Aghion, Professeur at Collège de France and at London School of Economics, member of Société économétrique and American Academy of Arts and Sciences.
Jan-Philipp Beck, CEO EIT Health
Thierry Breton, Commissioner at European Commission, Internal Market
Stewart Cole, Managing Director at l'Institut Pasteur

3:15 – 4:00 PM : Winning together : Successful corporate, healthtech companies and academic collaborations

Facilitator : Paul Barrett

Speakers :

1. Donna Armentano, Executive Director External R&D Innovation and Global Head Gene Therapy at Pfizer & Jean-Philippe Combal, PharmD, Ph.D co-founder & CEO at Vivet Therapeutics
2. Pr Jean-Yves Blay, Managing Director at Centre Léon Bérard and Président of Unicancer & Dominique Costantini, Chairman and Director of early development chez OSE Immunotherapeutics
3. Amaury Martin, Director, Technology transfer and Industrial partnerships, Institut Curie. & Luigi Ravagnan, Director, Strategic Collaborations, Global Medical, Bristol Myers Squibb

4:00 – 5:00 PM : Why & How setting an efficient corporate governance in innovative firms to support growth ?

Moderated by Lilian Stern, founder of Stern IR

Speakers :

Elsy Boglioli, CEO of Bio-up
Virginie Lléu, Founder and Executive director of L3S Partnership
Cédric Moreau, Partner at Sofinnova Partners
Nawal Ouzren, CEO of Sensorion

5:30 – 6:30 PM : Impact of the Covid-19 crises on financing opportunities and risks

Moderated by : Alain Pujol, Angels Santé Board member

Speakers :

Nissim Darvish, Partner Orbimed (Tel Aviv)
Marc Le Bozec, Fund Manager at Financières Arbevel
Camille Leca, Head of Listing France at Euronext
Philippe Monteyne, Partner @Fund+
Antoine Papiernik, Chairman & Managing Partner at Sofinnova Partners

6:30 – 7:00 PM : Value creation through smart partnerships. The biotech & pharma perspectives

Facilitator : Paul Barrett

Speakers :

Jean-Paul Kress, CEO at MorphoSys AG
Alban De La Sablière, SVP Global Head of Sanofi Partnering.

7:15 PM : Cocktail Reception

Agnès Pannier-Runacher, Minister Delegate to the Minister of the Economy, Finance and Recovery, in charge of Industry

PROGRAM 2020

<https://htid-paris.streameo.fr>



October 5th – Salon Lobby

2:00 – 2:30 PM : New EU regulations in the Medtech sector

Moderated by Alexandre Regniault, Lawyer at Simmons & Simmons

Speakers :

Marc Julien, Co-CEO Diabeloop

Lionel Dreux, President at GMED

Stéphane Piat, Managing Director at Carmat

Gary Slack, Senior Vice President Global Medical Devices at BSI.

2:30 – 3:00 PM : Medtech – Market Access

Moderated by Samuel Levy, Founding Partner at Lauxera Capital Partners

Speakers :

Graeme Brookes, CEO at Reapplix

Whitney Cypes, Vice President Global Marketing at Allurion Technologies

3:30 – 4:30 PM : VCoE : Innovating for Innovators

Speakers :

Jean-Marc Bourez, EIT Health France Managing Director and Head of the VCoE

Rémi Charrier, Global Head of Institutional Client Relationship, European Investment Fund

Stephan Christgau, Founding Partner, Eir Ventures

VP Value-based health & Innovation lead Europe, Amgen

Marc Julien, CEO, Diabeloop

Tomasz Kozlowski, Head of Mandate and Product Development, European Investment Fund

Patric Gresko, Head of Division – Innovation and Technology Investments, European Investment Fund

Henrik Matthies, Managing Director, Health Innovation Hub (HIH) Germany

Anne Osdoit, Partner, Sofinnova Partners (MDStart Fund)

Thomas Trailov, Director Strategy & Insights | World Business Line Healthcare, Air Liquide Santé International

4:30 – 5:00 PM : Keynote on entrepreneur & VC success (Corvidia Therapeutics learning experience)

Facilitator : Paul Barrett

Speakers :

Marc de Garidel, Chief Executive Officer at Corvidia Therapeutics

Graziano Seghezzi, Managing Partner at Sofinnova Partners

5:30 – 6:30 PM : Opportunities and challenges for Innovative healthtech companies in Europe (Bio-Deutschland & France Biotech)

Moderated by

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Oliver Schacht, PhD, Bio Deutschland President

Speakers

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Jack Elands, CEO Emergence AG

Mondher Mahjoubi, CEO Innate Pharma

Oliver Schacht, PhD, Bio Deutschland President

Jan Schmidt-Brand, CEO/CFO Heidelberg Pharma

6:30 – 7:15 PM : Opportunities in setting stronger relationship between, health industry & patient association

Speakers :

Dominique Pon, Minister Collaborator – Strategic Manager of the digital transformation in health & Managing Director of the

Clinique Pasteur in Toulouse

Gérard Raymond, President of France Assos Santé

PROGRAM 2020

<https://htid-paris.streameo.fr>



October 6th – Salon Etoile

8:30 – 11:30 AM : Cellular therapy & gene therapy: where do we stand, what perspectives?

Moderator : Christian Policard, Founding Partner at Biotech Développement Conseils

Chairmen : Pr Fabrice André , Head of Research, Gustave Roussy Institute, Villejuif & Frederic Revah, CEO, Genethon

Speakers :

Sebastian Amignorena, Research Director at Institut Curie, CNRS

Nathalie Cartier-Lacave, Director, NeuroGenCell Brain Lab and Spine Institute (ICM), Pitie-Salpetriere Hospital, Paris

Marina Cavazzana, Head of the Biotherapy Department at Necker Hospital and Imagine Institute

Patrick Henno, Co-founder of EMERCell

Mohamad Mohty, Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and University Pierre & Marie Curie

Jean-Antoine Ribeil, Medical Director in Medical Affairs Department at Bluebird Bio

11:30 – 12:15 PM : Renewed appetite for Medtech markets : VC/ Medtech duo

Moderated by André Michel Ballester

Speakers

Scott Bardo, Senior Healthcare Analyst at Berenberg Bank

Tim Haines, Chairman and Managing Partner at Abingworth

Sacha Loiseau, Venture Partner at Elaia

Bertin Nahum, Founder and President of Quantum Surgical

1:15 – 2:30 PM : Facing Covid-19 : challenges for Biotechs and Pharmas

Moderated by Eric Falcand, Global Head of Business Development and Licensing, Servier & Christian Policard, Founding Partner at Bio Développement Conseil (France)

Speakers :

Hugues Bultot, Co-founder and Chief Executive Officer Univercells

Christian Deleuze, Chairman of the Research & Innovation Commission at Leem

Rahim Fandi, Chief Medical Officer, Oxford Biotherapeutics

Laurent Levy, Co-founder and Chief Executive Officer Nanobiotix

Olivier Madec, Global Head of M&A and Venture Investments Servier

Frédéric Rothenburger, Managing Director at Lazard

Jacques Volckmann, Head R&D France, at Sanofi

2:45 – 3:45 PM : Manufacturing challenges and step forwards in new therapies

Facilitator : Paul Barrett

Speakers :

Serge Braun, Scientific Director at AFM Telethon

Frédéric Collet, Président at Leem (Les Entreprises du Médicament)

Richard Snyder, Vice President, Science and Technology Pharma Services, Viral Vector Services at ThermoFisher

Antoine Jourdan, Health Project Director at Direction Générale des Entreprises

4:15 – 5:30 PM : Amgen & EIT Health plenary session, Unleashing the true potential of AI in healthcare, together

Facilitator : Paul Barrett

Speakers :

Jean-Marc Bourez, Managing Director & Head of the VCoE, EIT Health France

David Dellamonica, Head Value Based Partnership & Digital innovation, DEEP AI Platform founder, Amgen Europe

Frederic Jean, Co-developer, Digital Medical Hub AP-HP

Henrik Matthies, Managing Director, Health Innovation Hub (HIH, Germany)

Philippe Menu, CMO SophiA Genetics

Karl Neuberger, Partner at Quantmetry

Arnaud Rosiers, CEO, Implicity

Stéphane Tholander, CEO & Co-Founder of Cibiltech

Stéphanie Trang, Managing Director of the AI for Health Initiative at Start-up Inside

Nicolas Villain, Director of the Research Department and AI HUB, Philips Healthcare

5:30 – 6:30 PM : Closing ceremony & Cocktail

PROGRAM 2020

<https://htid-paris.streameo.fr>



October 6th – Salon Lobby

8:45 – 9:45 AM : VCoE : EIF Market Insights (VCoE restricted plenary)

10:15 AM – 12:15 PM : VCoE : Shaping the Member Community Vision and Discussion (VCoE restricted plenary)

1:15 – 2:15 PM : Key Collaboration and Financing Issues during the Covid-19 Pandemic

Moderator

Paul Barrett

Speakers :

Anne-Charlotte Rivière, Partner, Paris at Dechert

David Schulman, Partner, Washington D.C. at Dechert

2:45 – 3:45 PM : Behavior of stakeholders in high volatility innovative markets like HealthTech

Moderated by

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP France Biotech

Speakers :

Professor Randall Kroszner, Deputy Dean for Executive Programs and Norman R. Bobins Professor of Economics at University of Chicago Booth

Professor Scott Meadow, Clinical Professor of Entrepreneurship at University of Chicago Booth

4:15 – 5:30 PM : Creating a New Culture of Innovation through Collaboration: the Bridging Academia with Industry Paradigm Shift

Moderated by

Gabriela Apiou, PhD, Director of Strategic Alliances at Mass General Research Institute and Assistant Professor of Dermatology at Harvard Medical School

& Robert Tepper, MD, Partner at Third Rock Ventures and Member of the Mass General Research Institute Advisory Council.

Speakers :

Patrick Fortune, PhD, Vice President, Market Sector at Mass General Brigham Innovation Office

Saptarsi Haldar, MD, Vice President of Research and Head of Cardometabolic Discovery at Amgen

Anthony Rosenzweig, MD, Chief of the Cardiology Division at Mass General Hospital

5:30 – 6:30 PM : Closing ceremony & Cocktail

Replays of the HTID round tables : <https://htid-paris.streameo.fr>

About HealthTech For Care



The HealthTech For Care endowment fund, launched by France Biotech, is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. The missions of the endowment fund are structured around three main areas: Supporting the development of the entire health ecosystem, accelerating the development of innovative therapies and treatments, and promoting better access to healthcare for patients in the French healthcare system and more widely throughout Europe. HealthTech For Care is administrated by Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.

About EIT Health



Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and growing multi-morbidity are all placing pressure on health systems across Europe.

EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.

From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU.

EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.
For more information visit: www.eithealth.eu

About France Biotech



Founded in 1997, France Biotech is an independent association that brings together the country's leading innovative health companies and their expert partners. As a leader in health innovation and a privileged intermediary with public authorities in France and Europe, France Biotech's mission is to support the development of this industry in France, by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry. France Biotech also aims to turn French innovative health technology companies into world leaders capable of designing and developing new innovations quickly and make them available and accessible to patients. France Biotech has founded and is developing the « HealthTech For Care » fund to strengthen the ability to federate, structure and encourage cooperation between the various stakeholders in the health tech sector in France and Europe. France Biotech is chaired since September 2019 by Franck Mouthon, CEO of Theranexus...

KEY NUMBERS 2020



2 Days in Paris and
in virtual
October 5&6, 2020



Hybrid event



Support
From Europe
and France



780
Participants



19
Conferences with
experts and KOLs



1000
Private meetings



15
Pharmaceutical
groups



300
Investors from all
around the world



150
HealthTech
Companies

Looking forward to seeing
you for Healthtech
Innovation Days 3 in
2021 !

Thanks to our partners



Platinum



Super Gold



Gold



Silver



Bronze



Social Media & Contacts



HealthTech Innovation Days
<https://www.linkedin.com/company/htid>



HealthTech Innovation Days
https://twitter.com/HTID_Paris



HealthTech For Care
<http://htfc-eu.com>



EIT Health is supported by the EIT, a body of the European Union

Estelle Metzger
Project Manager Junior
estelle.metzger@htfc-eu.com
+33 (0)6 38 03 80 60

Solene Goupy
Communication Manager
solene.goupy@htfc-eu.com
+33 (0)6 38 03 80 19

Nathalie Donne
Senior Advisor Manager
nathalie.donne@insead.eu
06 67 67 44 97